HLA-DRB1 and myeloid sarcoma: Recent studies show that HLA‐DRB1 and MERTK genotypes independently influence MS risk by modulating monocyte behaviour, with the DR15 haplotype linked to reduced proportions of CD14+ MERTK+ monocytes, and the MERTK SNP rs7422195 affecting MERTK expression in monocytes [32].